Nyxoah SA (NYXH) Form 6-K — Jun 4, 2026
Nyxoah SA announced a leadership transition on June 4, 2026, initiating a search for a new U.S.-based Chief Executive Officer to accelerate commercial traction in the United States. Current CEO Olivier Taelman will remain engaged during the transition period to ensure a smooth handover. The company reported strong operational momentum in the U.S., with active accounts growing 60% quarter-over-quarter to 91, and 207 surgeons trained on the Genio system since August 2025. In Germany, Nyxoah achieved a 25% market share within 24 months of launch and saw 53% implant growth in 2025.
Key figures
- Revenue
- 0
- Net Income
- 0
- Total Debt
- 0
- Cash Position
- €25.9 million
- Cash runway end
- Q3 2026
- Us active accounts
- 91
- Accumulated deficit
- €321.7 million
- Atm program capacity
- $200.0 million
- Germany market share
- 25%
- Surgeons trained total
- 207
- Atm shares sold to date
- $32.8 million
- Dream trial success rate
- 82%
- Surgeons trained q1 2026
- 62
- Germany implant growth 2025
- 53%
- Us active accounts growth qoq
- 60%
- Prior authorizations submitted
- 241
- Total equity raised since inception
- €332.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.